FOB Price : Get a Price/Quote
Min.Order : 1 Set(s)
Certification : CFDA,GMP,ISO13485,CE,FDA
Brand Name : LYHER
Payment Terms : T/T,D/P,PayPai,WesternUnion,MoneyGram
brand name : LYHER
certification : CFDA,GMP,ISO13485,CE,FDA
min.order : 1 Set(s)
warranty :
payment terms : T/T,D/P,PayPai,WesternUnion,MoneyGram
Packaging :
Specification :
place of origin : Zhejiang
Test | Sepecimen | Range | Clinical application | |
Infection | PCT | Whole blood/Serum/Plasma |
0.1-100ng/ml | Best Indicator of Infection & Sepsis |
CRP | Whole blood/Serum/Plasma |
5-200mg/L | Differential diagnosis virus infection and bacteral infection | |
Cardiology | hsCRP | Whole blood/Serum/Plasma |
0.5-5mg/L | Cardiovascalar disease risk |
CTnI | Whole blood/Serum/Plasma |
0.1-50ng/ml | Myocardial infarction risk signal: >0.3ng/ml | |
CK-MB | Whole blood/Serum/Plasma |
3~100ng/mL | Myocardial infarction risk signal: 5ng/ml | |
MYO | Whole blood/Serum/Plasma |
5~500ng/mL | Myocardial infarction risk signal: 50ng/ml | |
NT-proBNP | Whole blood/Serum/Plasma |
100~32000 pg/mL | Heart failure risk signal: >300pg/ml |
Tumor | PSA | Serum/Plasma | 0.5-100ng/mL | Prostate cancer risk: PSA>4.0ng/mL |
AFP | Serum/Plasma | 5-350ng/mL | Primary liver cancer risk: AFP>20ng/mL | |
CEA | Serum/Plasma | 3-500ng/mL | Colorectal cancer, stomach cancer, lung cancer, liver cancer, pancreatic cancer risk: CEA>5.0ng/mL | |
Allergy | Total IgE | Whole blood/Serum/Plasma |
5-1000 IU/mL |
Allergic diseases, worm, eczema or non-eczema dermatitis, IgE myeloma risk: Total IgE>100IU/mL |
Ordinary verified
Business Type Service
Country / Region Zhejiang,China
Main Products In vitro Diagnosis Consumables, In vitro Diagnosis Reagents, Diagnostic Tests
Main Markets Southeast Asia, Mid East, Africa, Europe,South Asia
brand name : LYHER
certification :
fob price :
min.order : 1 Set(s)
warranty :
payment terms : T/T,D/P,PayPai,WesternUnion,MoneyGram
Packaing :
Specification :
Trademark : LYHER
Production Capacity :
place of origin : Zhejiang
Manag Certifica : CFDA,GMP,ISO13485,CE,FDA
Test | Sepecimen | Range | Clinical application | |
Infection | PCT | Whole blood/Serum/Plasma |
0.1-100ng/ml | Best Indicator of Infection & Sepsis |
CRP | Whole blood/Serum/Plasma |
5-200mg/L | Differential diagnosis virus infection and bacteral infection | |
Cardiology | hsCRP | Whole blood/Serum/Plasma |
0.5-5mg/L | Cardiovascalar disease risk |
CTnI | Whole blood/Serum/Plasma |
0.1-50ng/ml | Myocardial infarction risk signal: >0.3ng/ml | |
CK-MB | Whole blood/Serum/Plasma |
3~100ng/mL | Myocardial infarction risk signal: 5ng/ml | |
MYO | Whole blood/Serum/Plasma |
5~500ng/mL | Myocardial infarction risk signal: 50ng/ml | |
NT-proBNP | Whole blood/Serum/Plasma |
100~32000 pg/mL | Heart failure risk signal: >300pg/ml |
Tumor | PSA | Serum/Plasma | 0.5-100ng/mL | Prostate cancer risk: PSA>4.0ng/mL |
AFP | Serum/Plasma | 5-350ng/mL | Primary liver cancer risk: AFP>20ng/mL | |
CEA | Serum/Plasma | 3-500ng/mL | Colorectal cancer, stomach cancer, lung cancer, liver cancer, pancreatic cancer risk: CEA>5.0ng/mL | |
Allergy | Total IgE | Whole blood/Serum/Plasma |
5-1000 IU/mL |
Allergic diseases, worm, eczema or non-eczema dermatitis, IgE myeloma risk: Total IgE>100IU/mL |